{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:33:15Z","timestamp":1773423195664,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO1CA140285"],"award-info":[{"award-number":["RO1CA140285"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA041108"],"award-info":[{"award-number":["P01CA041108"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA023074"],"award-info":[{"award-number":["P30CA023074"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12029-020-00515-8","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T03:47:28Z","timestamp":1599882448000},"page":"940-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0030-8737","authenticated-orcid":false,"given":"Ana","family":"Florea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann C.","family":"Klimentidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay N.","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Jurutka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth T.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"515_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"515_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177\u201393.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"515_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"3","key":"515_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/ni.3384","volume":"17","author":"A Lasry","year":"2016","unstructured":"Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nat Immunol. 2016;17(3):230\u201340.","journal-title":"Nat Immunol"},{"issue":"13","key":"515_CR5","doi-asserted-by":"publisher","first-page":"20543","DOI":"10.18632\/oncotarget.16129","volume":"8","author":"MD Dela Cruz","year":"2017","unstructured":"Dela Cruz MD, Ledbetter S, Chowdhury S, Tiwari AK, Momi N, Wali RK, et al. Metabolic reprogramming of the premalignant colonic mucosa is an early event in carcinogenesis. Oncotarget. 2017;8(13):20543\u201357.","journal-title":"Oncotarget"},{"issue":"11","key":"515_CR6","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41416-018-0280-x","volume":"119","author":"J Qian","year":"2018","unstructured":"Qian J, Tikk K, Weigl K, Balavarca Y, Brenner H. Fibroblast growth factor 21 as a circulating biomarker at various stages of colorectal carcinogenesis. Br J Cancer. 2018;119(11):1374\u201382.","journal-title":"Br J Cancer"},{"key":"515_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"C Degirolamo","year":"2016","unstructured":"Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15:51\u201369.","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 2","key":"515_CR8","doi-asserted-by":"publisher","first-page":"015","DOI":"10.4172\/2155-9929.S2-015","volume":"1","author":"ME Knott","year":"2016","unstructured":"Knott ME, Minatta JN, Roulet L, Gueglio G, Pasik L, Ranuncolo SM, et al. Circulating fibroblast growth factor 21 (Fgf21) as diagnostic and prognostic biomarker in renal cancer. J Mol Biomarker Diag. 2016;1(Suppl 2):015. https:\/\/doi.org\/10.4172\/2155-9929.S2-015.","journal-title":"J Mol Biomarker Diag"},{"issue":"15 Suppl","key":"515_CR9","doi-asserted-by":"publisher","first-page":"Abstract no.157","DOI":"10.1158\/1538-7445.AM2015-1577","volume":"75","author":"ME Knott","year":"2015","unstructured":"Knott ME, Ranuncolo SM, Nu\u00f1ez M, Armanasco E, Puricelli LI, De Lorenzo MS. Levels of fibroblast growth factor 21 (FGF21) in serum as diagnostic biomarker in patients with breast cancer. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. Cancer Res. 2015;75(15 Suppl):Abstract no.1577. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-1577.","journal-title":"Cancer Res"},{"key":"515_CR10","doi-asserted-by":"publisher","unstructured":"Harlid S, Myte R, Van Guelpen B (2017). The metabolic syndrome, inflammation, and colorectal cancer risk: an evaluation of large panels of plasma protein markers using repeated, prediagnostic samples. Med Inflamm. https:\/\/doi.org\/10.1155\/2017\/4803156. Epub 2017 Mar 22.","DOI":"10.1155\/2017\/4803156"},{"issue":"11","key":"515_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/jnci\/dji144","volume":"97","author":"DS Alberts","year":"2005","unstructured":"Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst. 2005;97(11):846\u201353.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"515_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cgh.2012.09.026","volume":"11","author":"T Jess","year":"2013","unstructured":"Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11(1):43\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9809","key":"515_CR13","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","volume":"378","author":"J Burn","year":"2011","unstructured":"Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081\u20137.","journal-title":"Lancet"},{"issue":"3","key":"515_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0016-5085(91)90519-Q","volume":"101","author":"D Labayle","year":"1991","unstructured":"Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterol. 1991;101(3):635\u20139.","journal-title":"Gastroenterol"},{"issue":"1","key":"515_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00441-010-1024-2","volume":"342","author":"N Itoh","year":"2010","unstructured":"Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010;342(1):1\u201311.","journal-title":"Cell Tissue Res"},{"issue":"4","key":"515_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1073\/pnas.1514511113","volume":"113","author":"Y-H Youm","year":"2016","unstructured":"Youm Y-H, Horvath TL, Mangelsdorf DJ, Kliewer SA, Dixit VD. Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. PNAS. 2016;113(4):1026\u201331.","journal-title":"PNAS"},{"issue":"2","key":"515_CR17","first-page":"77","volume":"2","author":"LJ Hanks","year":"2015","unstructured":"Hanks LJ, Guti\u00e9rrez OM, Bamman MM, Ashraf A, McCormick KL, Casazza K. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl. 2015;2(2):77\u201382.","journal-title":"J Clin Transl"},{"issue":"3","key":"515_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-2005-916274","volume":"18","author":"F Amersi","year":"2005","unstructured":"Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005;18(3):133\u201340. https:\/\/doi.org\/10.1055\/s-2005-916274.","journal-title":"Clin Colon Rectal Surg"},{"key":"515_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41021-016-0033-0","volume":"38","author":"T Hamoya","year":"2016","unstructured":"Hamoya T, Fujii G, Miyamoto S, Takahashi M, Totsuka Y, Wakabayashi K, et al. Effects of NSAIDs on the risk factors of colorectal cancer: a mini review. Genes Environ. 2016;38:6. https:\/\/doi.org\/10.1186\/s41021-016-0033-0.","journal-title":"Genes Environ"},{"issue":"9754","key":"515_CR20","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"76","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;76(9754):1741\u201350.","journal-title":"Lancet"},{"issue":"1","key":"515_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-230X-13-67","volume":"13","author":"C Yang","year":"2013","unstructured":"Yang C, Lu W, Lin T, You P, Ye M, Huang Y, et al. Activation of liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol. 2013;13(1):67.","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"515_CR22","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2337\/db14-0595","volume":"63","author":"KR Markan","year":"2014","unstructured":"Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014;63(12):4057\u201363.","journal-title":"Diabetes."},{"issue":"4","key":"515_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/CBM-161507","volume":"18","author":"M Akyol","year":"2017","unstructured":"Akyol M, Alacacioglu A, Demir L, Kucukzeybek Y, Yildiz Y, Gumus Z, et al. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. Cancer Biomark. 2017;18(4):441\u20139.","journal-title":"Cancer Biomark"},{"issue":"8","key":"515_CR24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","volume":"32","author":"AO Chavez","year":"2009","unstructured":"Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32(8):1542\u20136.","journal-title":"Diabetes Care"},{"issue":"3","key":"515_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","volume":"71","author":"M Mraz","year":"2009","unstructured":"Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol. 2009;71(3):369\u201375.","journal-title":"Clin Endocrinol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-020-00515-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:02:57Z","timestamp":1631404977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-020-00515-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s12029-020-00515-8","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"7 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study has been approved by the University of Arizona Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written and signed informed consent forms.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants provided written and signed informed consent forms.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"No special or custom code was used.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}